SCHEMBL16291997

SCHEMBL16291997

O=C(O)N1C=CC=CC1c1ccccn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPEPPS P55786 1/20 0.38
KDM4E B2RXH2 3/20 0.37
HSD17B10 Q99714 2/20 0.37
KMT2A Q03164 3/20 0.37
KDM4A O75164 2/20 0.36
KDM6B O15054 1/20 0.36
KDM5C P41229 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM2A Q9Y2K7 1/20 0.36
KDM3A Q9Y4C1 1/20 0.36
ALDH1A1 P00352 4/20 0.36
CASP1 P29466 2/20 0.36
LMNA P02545 1/20 0.36
NAPRT Q6XQN6 1/20 0.36
P4HTM Q9NXG6 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL28890119 0.85 PKM (0.40) NPEPPSKDM4EHSD17B10KMT2AALDH1A1
SCHEMBL4639335 0.81 GPR119 (0.43) NPEPPSKDM4EHSD17B10ALDH1A1CASP1
SCHEMBL31097820 0.78 P4HA1 (0.46) HSD17B10ALDH1A1LMNANAPRTP4HTM
SCHEMBL23053142 0.74 ALDH1A1 (0.40) NPEPPSKDM4EHSD17B10KMT2AALDH1A1
SCHEMBL7939397 0.74 ALDH1A1 (0.36) NPEPPSKDM4EHSD17B10KMT2AALDH1A1
SCHEMBL10649891 0.66 ALDH1A1 (0.45) KDM4EHSD17B10KMT2AALDH1A1CASP1
SCHEMBL31228434 0.65 HSD11B1 (0.49) LMNANAPRTP4HTML3MBTL1RIPK1
SCHEMBL1740411 0.65 HSD11B1 (0.49) LMNANAPRTP4HTML3MBTL1RIPK1
SCHEMBL12915391 0.65 KDM4E (0.46) KDM4EHSD17B10KMT2AALDH1A1LMNA
SCHEMBL23280559 0.63 KDM4E (0.44) KDM4EHSD17B10KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4444312-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 EP disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
US-9073856-B2 Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors ELI LILLY AND COMPANY (US) 2015-07-07 US disclosed
US-20140371269-A1 PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT-2 INHIBITORS ELI LILLY AND COMPANY (US) 2014-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371269-A1 PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT-2 INHIBITORS MGST1, MGAT1, MGAT2 NPEPPS 1070/4885KDM4E 2664/4885HSD17B10 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.